Caveats of Untargeted Metabolomics for Biomarker Discovery

Journal of the American College of Cardiology

Volumn 68, Issue 12, 2016, Pages 1294-1296

  Baig, Ferheen ^a   Pechlaner, Raimund ^b   Mayr, Manuel ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

liquid chromatography; mass spectrometry; metabolism; myocardial infarction

Indexed keywords

BIOLOGICAL MARKER;

CHINESE; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; DATA BASE; DISEASE CLASSIFICATION; DISEASE MARKER; EDITORIAL; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; METABOLITE; METABOLOMICS; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICAL RESEARCH;

BIOMARKERS; BIOMEDICAL RESEARCH; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; MASS SPECTROMETRY; METABOLOMICS;

EID: 84994910815     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.098     Document Type: Editorial

References (10)

1. 1 Fan, Y., Li, Y., Chen, Y., et al. Comprehensive metabolomic characterization of coronary artery diseases. J Am Coll Cardiol 68 (2016), 1281–1293.
2. 2 Wei, R., Li, G., Seymour, A.B., High-throughput and multiplexed LC/MS/MRM method for targeted metabolomics. Anal Chem 82 (2010), 5527–5533.
3. 3 Zhu, Z.J., Schultz, A.W., Wang, J., et al. Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database. Nat Prot 8 (2013), 451–460.
4. 4 Wishart, D.S., Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov 15 (2016), 473–484.
5. 5 Patti, G.J., Yanes, O., Siuzdak, G., Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13 (2012), 263–269.
6. 6 Furey, A., Moriarty, M., Bane, V., Kinsella, B., Lehane, M., Ion suppression; a critical review on causes, evaluation, prevention and applications. Talanta 115 (2013), 104–122.
7. 7 Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75 (2003), 3019–3030.
8. 8 Mayr, M., Metabolomics: ready for the prime time?. Circ Cardiovasc Genet 1 (2008), 58–65.
9. 9 Stegemann, C., Pechlaner, R., Willeit, P., et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation 129 (2014), 1821–1823.
10. 10 Mamas, M., Dunn, W.B., Neyses, L., Goodacre, R., The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 85 (2011), 5–17.